Poland· PL-100364041

Valarox

A rosuvastatin und valsartan product containing valsartanum + rosuvastatinum, registered in Poland by Krka, d.d., Novo mesto. The same ATC class is registered in 3 of our 19 countries.

ATC C10BX10

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedValaroxATCC10BX10REGISTER NO.PL-100364041PACKS LISTED10CHECKEDSeptember 27, 2026

Where it is registered

Rosuvastatin und valsartan is registered in 3 of 19 countries.

Countries holding a registration under ATC C10BX10 (rosuvastatin und valsartan), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose

Rosuvastatin und valsartan · ATC C10BX10

3 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Valsartanum + Rosuvastatinum
Manufacturer
Krka, d.d., Novo mesto
Country
Poland (PL)
ATC code
C10BX10
ATC class
Rosuvastatin und Valsartan
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 10

  • gtin
    05909991305031
  • gtin
    05909991305048
  • gtin
    05909991305055
  • gtin
    05909991305062
  • gtin
    05909991305079
  • gtin
    05909991305086
  • gtin
    05909991305093
  • gtin
    05909991305109
  • gtin
    05909991305116
  • gtin
    05909991305123

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Rosuvastatin und valsartan in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rosuvastatin und valsartan products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Ravalsya
  • Belgium · Rosuvastatin/Valsartan Hcs
  • Bulgaria · Валсарос
  • Czechia · Ravalsyo
  • Germany · Rosuvalsa Apontis
  • Estonia · Valarox
  • Spain · Valsaros
  • Hungary · Ravalsyo
  • Lithuania · Ravalsyo
  • Latvia · Valarox
  • Portugal · Valarox
  • Romania · Valarox
  • Slovenia · Ravalsyo
  • Slovakia · Ravalsya

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0d1bdd9f-ec01-445f-9de0-c7d47cf590b7
GET /v1/drugs/0d1bdd9f-ec01-445f-9de0-c7d47cf590b7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "160 mg + 10 mg",
  "packaging": "05909991305031 ¦ Rp ¦ 118969\n10 tabl.\n05909991305048 ¦ Rp ¦ 118970\n14 tabl.\n05909991305055 ¦ Rp ¦ 118971\n20 tabl.\n05909991305062 ¦ Rp ¦ 118972\n28 tabl.\n05909991305079 ¦ Rp ¦ 118973\n30 tabl.\n05909991305086 ¦ Rp ¦ 118974\n56 tabl.\n05909991305093 ¦ Rp ¦ 118975\n60 tabl.\n05909991305109 ¦ Rp ¦ 118976\n84 tabl.\n05909991305116 ¦ Rp ¦ 118977\n90 tabl.\n05909991305123 ¦ Rp ¦ 118978\n100 tabl.",
  "substance": "Valsartanum 160 mg + Rosuvastatinum 10 mg",
  "common_name": "Valsartanum + Rosuvastatinum",
  "pl_product_id": "100364041",
  "pozwolenie_nr": "23568",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}

See everything about rosuvastatin und valsartan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.